Get the Stockscreener App
13.17
0.61%
0.08
After Hours:
13.07
-0.10
-0.76%
Gh Research Plc stock is traded at $13.17, with a volume of 236.39K.
It is up +0.61% in the last 24 hours and down -2.52% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$13.09
Open:
$13.21
24h Volume:
236.39K
Relative Volume:
0.87
Market Cap:
$685.21M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-16.67
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
-2.95%
1M Performance:
-2.52%
6M Performance:
+46.82%
1Y Performance:
+104.50%
1-Day Range:
$12.85
$13.54
1-Week Range:
$12.67
$13.79
52-Week Range:
$6.189
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
13.17 | 811.96M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
How GH Research PLC stock responds to policy changesPrice Action & Daily Stock Momentum Reports - newser.com
Market reaction to GH Research PLC’s recent newsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Can volume confirm reversal in GH Research PLCQuarterly Risk Review & High Win Rate Trade Alerts - newser.com
Will GH Research PLC stock outperform international peers2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Has GH Research PLC found a price floorJuly 2025 Summary & Real-Time Volume Analysis Alerts - newser.com
Does GH Research PLC qualify in momentum factor screeningMarket Activity Summary & Safe Investment Capital Preservation Plans - newser.com
Is GH Research PLC stock cheap at current valuationBuy Signal & Verified Swing Trading Watchlists - newser.com
Will GH Research PLC stock benefit from automationWall Street Watch & Low Drawdown Investment Ideas - newser.com
Why millennials buy GH Research PLC (1KA) stockJuly 2025 Fed Impact & AI Driven Price Forecasts - newser.com
Is GH Research PLC stock a buy in volatile markets2025 Top Gainers & Reliable Volume Spike Trade Alerts - newser.com
What drives GH Research PLC 1KA stock priceMonthly Performance Summary & Free Smart Trading Classes - earlytimes.in
H.C. Wainwright maintains buy on GH Research stock, $40 target - MSN
GH Research PLC Stock Analysis and ForecastPrice Action Trading & Small Entry Cost Investments - Early Times
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):